Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Nausea and vomiting are two of the more concerning adverse outcomes associated with
chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer
patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with
carboplatin and paclitaxel. The successful control of chemotherapy induced nausea and
vomiting (CINV) is thus, of paramount importance in ensuring optimal treatment and sustaining
a cancer patient's quality of life.